Promising predictors of checkpoint inhibitor response in NSCLC-Reference-Cited by-同舟云学术

Promising predictors of checkpoint inhibitor response in NSCLC

Published:2020-09-09 Issue:11 Volume:20 Page:931-937
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Alex Friedlaender¹,Alfredo Addeo¹^ORCID

Affiliation:

1. Department of Oncology, University Hospital Geneva, Geneva, Switzerland

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2020.1816173

Reference59 articles.

1. Howlader NNA, Krapcho M, Miller D, et al. SEER cancer statistics review, 1975–2014. Bethesda: National Cancer Institute; 2017 [cited 2020 Apr 10]. Available from: https://seercancergov/csr/1975_2014/

2. Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era

3. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

4. Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study;Frontiers in Immunology;2024-07-23

2. Prognostic value of immunotherapy in advanced NSCLC based on baseline and dynamic changes in HALP;Biomolecules and Biomedicine;2024-07-14

3. Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions;ESMO Open;2023-02

4. High Neutrophil-to-Lymphocyte Ratio Facilitates Cancer Growth—Currently Marketed Drugs Tadalafil, Isotretinoin, Colchicine, and Omega-3 to Reduce It: The TICO Regimen;Cancers;2022-10-10

5. Influence of concomitant gastric acid suppressants use on the survival of patients with non-small cell lung cancer treated with programmed death-1/ligand-1 inhibitors: A meta-analysis;International Immunopharmacology;2022-09